These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30232604)

  • 1. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
    Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
    Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
    Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
    Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
    Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.
    Kim IK; Kim BG; Kim W; Kim D; Kim YJ; Yoon JH; Lee HS
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5511-9. PubMed ID: 22890764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
    Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
    J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
    Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
    Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY; Chandrasekar PH; Masood A; Schiffer CA
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
    Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
    Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.
    Wu XY; Li X; Chen ZH; Wen JY; Lin Q; Xing YF; Dong M; Wei L; Wang TT; Chen J; Lin ZX; Wan XB; Ruan DY; Ma XK
    Tumour Biol; 2013 Apr; 34(2):909-18. PubMed ID: 23269606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
    Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
    Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.